SPECIAL REPORT

Nicox gains rights to AMD test

Nicox announced today that it is expanding its diagnostic portfolio with RetnaGene, a test to predict a patient's risk of progressing to late-stage or wet age-related macular degeneration (AMD). The company plans to promote the test in the U.S. during the first half of 2014. » Full article

Editorial Questions? Contact the Editorial Team. Click Here.
Sales, Reprints, Classified questions? Contact the Sales Team. Click Here.